Skip to content
Grifols logo — Develops, produces and provides innovative healthcare servic...

Grifols

Develops, produces and provides innovative healthcare services and solutions in more than 110 countries

Founded 1940 73 employees IPO Total: $1.86B Biotechnology, Health Care +1

General Information

Company Name Grifols
Founded Year 1940
Employees 73
Industries Biotechnology, Health Care, Manufacturing
Funding Stage IPO
Business Model B2B, B2C
Revenue Model Product Sales, Service Fee, Licensing
Social

BounceWatch is an independent company data service, not affiliated with Grifols. To contact Grifols, visit grifols.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Grifols compare?

A PDF of Grifols and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Grifols soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Grifols

Grifols stands as a venerable force in the global healthcare sector, with a history dating back to 1940. Originating from the collaborative vision of hematologist Josep Antoni Grífols i Roig and his sons in post-war Barcelona, the company has transformed from a family-run lab into a powerhouse in Biotechnology, Health Care, and Manufacturing.

Renowned for pioneering innovations, Grifols made significant strides in medical sciences, notably in plasmapheresis technology since 1951. Their slogan, "Develops, produces and provides innovative healthcare services and solutions in more than 110 countries", encapsulates their expansive reach and commitment to medical advancements.

Recently, Grifols secured a substantial €1.30 billion post-IPO debt investment in late 2024, a testament to sustained investor confidence. This sizable influx of capital signals a robust growth trajectory, enticing potential investors looking for stability in a longstanding market leader with a footprint in over 110 countries.

Business keywords: healthcare services, clinical analysis, freeze-dried plasma, plasmapheresis, Bioscience, plasma derivatives, Hospital segment, Diagnostic products, laboratory analysis, blood banks, transfusion centers, global healthcare

Services & Products

development and production of innovative medicines
plasma science research
diagnostic solutions
healthcare solutions for hospitals
bio supplies

Target Customers

patients with chronic and rare diseases hospitals healthcare professionals medical researchers biotechnology companies

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Debt €1.30B -
01 Dec 2024
Post-IPO Debt €300.00M -
01 Jun 2024
Secondary Market €250.00M 1
JPMorgan
01 Mar 2024
Grant $12.55M -
01 Apr 2020
IPO Undisclosed -
01 Jun 2011
IPO Undisclosed -
01 May 2006

Grifols Alternatives & Competitors

View All Alternatives
Grifols vs
EUSA Pharma
EUSA Pharma United Kingdom

Part of Recordati Rare Diseases, the business unit dedicated to rare diseases in the Recordati group...

Venture round
107 employees
Biotechnology, Health Care
Grifols vs
Biogen
Biogen United States

Innovative therapies worldwide for people living with serious neurological and neurodegenerative dis...

IPO
7823 employees
Biotechnology, Health Care
Grifols vs

Focused on creating and delivering engineered cells as medicines for patients

IPO
257 employees
Biotechnology, Health Care

FAQ About Grifols

Develops, produces and provides innovative healthcare services and solutions in more than 110 countries
Grifols was founded in 1940.
Grifols operates in Biotechnology, Health Care and Manufacturing. Its work centres on healthcare services, clinical analysis, freeze-dried plasma and plasmapheresis. Its customers include patients with chronic and rare diseases, hospitals and healthcare professionals.
Grifols has a B2B and B2C business model. Its revenue comes from Product Sales, Service Fee and Licensing.
Grifols has approximately 73 employees.
Grifols has completed 6 funding rounds, raising a total of $1.86B. The latest funding stage is IPO.
Grifols offers: development and production of innovative medicines, plasma science research, diagnostic solutions, healthcare solutions for hospitals, bio supplies.
Top alternatives and competitors to Grifols include EUSA Pharma, Biogen, Sana Biotechnology, Inc., Solid Biosciences, Kansas Laboratories Co.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Grifols and EUSA Pharma are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Grifols, https://bouncewatch.com/company/grifols, updated 11 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout